PDF herunterladen
Semin Thromb Hemost 2017; 43(08): 814-826
DOI: 10.1055/s-0036-1598003
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Factor XII Contact Activation

Clément Naudin
1   Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm, Sweden
2   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
,
Elena Burillo
1   Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm, Sweden
2   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
,
Stefan Blankenberg
3   Department of General and Interventional Cardiology, University Heart Center Hamburg-Eppendorf, Hamburg, Germany
,
Lynn Butler
1   Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm, Sweden
2   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
,
Thomas Renné
1   Clinical Chemistry, Department of Molecular Medicine and Surgery, Karolinska Institutet and University Hospital, Stockholm, Sweden
2   Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
27. März 2017 (online)

    Lizenzen und Reprints

Abstract

Contact activation is the surface-induced conversion of factor XII (FXII) zymogen to the serine protease FXIIa. Blood-circulating FXII binds to negatively charged surfaces and this contact to surfaces triggers a conformational change in the zymogen inducing autoactivation. Several surfaces that have the capacity for initiating FXII contact activation have been identified, including misfolded protein aggregates, collagen, nucleic acids, and platelet and microbial polyphosphate. Activated FXII initiates the proinflammatory kallikrein-kinin system and the intrinsic coagulation pathway, leading to formation of bradykinin and thrombin, respectively. FXII contact activation is well characterized in vitro and provides the mechanistic basis for the diagnostic clotting assay, activated partial thromboplastin time. However, only in the past decade has the critical role of FXII contact activation in pathological thrombosis been appreciated. While defective FXII contact activation provides thromboprotection, excess activation underlies the swelling disorder hereditary angioedema type III. This review provides an overview of the molecular basis of FXII contact activation and FXII contact activation–associated disease states.

Keywords

FXII - contact activation - aPTT - polyphosphate - thrombosis
 

  • References

  • 1 Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451 (7181): 914-918
    CrossrefPubMedGoogle Scholar
  • 2 Dahlbäck B. Coagulation and inflammation--close allies in health and disease. Semin Immunopathol 2012; 34 (01) 1-3
    CrossrefPubMedGoogle Scholar
  • 3 Long AT, Kenne E, Jung R, Fuchs TA, Renné T. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J Thromb Haemost 2016; 14 (03) 427-437
    CrossrefPubMedGoogle Scholar
  • 4 Engel R, Brain CM, Paget J, Lionikiene AS, Mutch NJ. Single-chain factor XII exhibits activity when complexed to polyphosphate. J Thromb Haemost 2014; 12 (09) 1513-1522
    CrossrefPubMedGoogle Scholar
  • 5 Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood 2012; 120 (22) 4296-4303
    CrossrefPubMedGoogle Scholar
  • 6 Maas C, Oschatz C, Renné T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37 (04) 375-381
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Kenne E, Nickel KF, Long AT. , et al. Factor XII: a novel target for safe prevention of thrombosis and inflammation. J Intern Med 2015; 278 (06) 571-585
    CrossrefPubMedGoogle Scholar
  • 8 Renné T, Dedio J, Meijers JC, Chung D, Müller-Esterl W. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J Biol Chem 1999; 274 (36) 25777-25784
    CrossrefPubMedGoogle Scholar
  • 9 Herwald H, Renné T, Meijers JC. , et al. Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4. J Biol Chem 1996; 271 (22) 13061-13067
    CrossrefPubMedGoogle Scholar
  • 10 Björkqvist J, Jämsä A, Renné T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110 (03) 399-407
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 11 Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood 2010; 115 (13) 2569-2577
    CrossrefPubMedGoogle Scholar
  • 12 Renné T, Dedio J, David G, Müller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000; 275 (43) 33688-33696
    CrossrefPubMedGoogle Scholar
  • 13 Renné T, Schuh K, Müller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans. J Immunol 2005; 175 (05) 3377-3385
    CrossrefPubMedGoogle Scholar
  • 14 Björkqvist J, Nickel KF, Stavrou E, Renné T. In vivo activation and functions of the protease factor XII. Thromb Haemost 2014; 112 (05) 868-875
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 15 Inoue Y, Peters LL, Yim SH, Inoue J, Gonzalez FJ. Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. J Mol Med (Berl) 2006; 84 (04) 334-344
    CrossrefPubMedGoogle Scholar
  • 16 Konings J, Govers-Riemslag JW, Philippou H. , et al. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011; 118 (14) 3942-3951
    CrossrefPubMedGoogle Scholar
  • 17 Gordon EM, Venkatesan N, Salazar R. , et al. Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proc Natl Acad Sci U S A 1996; 93 (05) 2174-2179
    CrossrefPubMedGoogle Scholar
  • 18 LaRusch GA, Mahdi F, Shariat-Madar Z. , et al. Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood 2010; 115 (24) 5111-5120
    CrossrefPubMedGoogle Scholar
  • 19 Citarella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem 1996; 238 (01) 240-249
    CrossrefPubMedGoogle Scholar
  • 20 Miyazawa K. Hepatocyte growth factor activator (HGFA): a serine protease that links tissue injury to activation of hepatocyte growth factor. FEBS J 2010; 277 (10) 2208-2214
    CrossrefPubMedGoogle Scholar
  • 21 Chen X, Wang J, Paszti Z. , et al. Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy. Anal Bioanal Chem 2007; 388 (01) 65-72
    CrossrefPubMedGoogle Scholar
  • 22 Mutch NJ, Waters EK, Morrissey JH. Immobilized transition metal ions stimulate contact activation and drive factor XII-mediated coagulation. J Thromb Haemost 2012; 10 (10) 2108-2115
    CrossrefPubMedGoogle Scholar
  • 23 Castaldi PA, Larrieu MJ, Caen J. Availability of platelet Factor 3 and activation of factor XII in thrombasthenia. Nature 1965; 207 (995) 422-424
    CrossrefPubMedGoogle Scholar
  • 24 Nielsen VG, Cohen BM, Cohen E. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII. Acta Anaesthesiol Scand 2005; 49 (02) 222-231
    CrossrefPubMedGoogle Scholar
  • 25 Bäck J, Sanchez J, Elgue G, Ekdahl KN, Nilsson B. Activated human platelets induce factor XIIa-mediated contact activation. Biochem Biophys Res Commun 2010; 391 (01) 11-17
    CrossrefPubMedGoogle Scholar
  • 26 Walsh PN, Griffin JH. Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 1981; 57 (01) 106-118
    PubMedGoogle Scholar
  • 27 Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279 (43) 44250-44257
    CrossrefPubMedGoogle Scholar
  • 28 Müller F, Mutch NJ, Schenk WA. , et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139 (06) 1143-1156
    CrossrefPubMedGoogle Scholar
  • 29 Smith SA, Choi SH, Davis-Harrison R. , et al. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116 (20) 4353-4359
    CrossrefPubMedGoogle Scholar
  • 30 Rao NN, Gómez-García MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. Annu Rev Biochem 2009; 78: 605-647
    CrossrefPubMedGoogle Scholar
  • 31 Szymusiak M, Donovan AJ, Smith SA. , et al. Colloidal confinement of polyphosphate on gold nanoparticles robustly activates the contact pathway of blood coagulation. Bioconjug Chem 2016; 27 (01) 102-109
    CrossrefPubMedGoogle Scholar
  • 32 Donovan AJ, Kalkowski J, Szymusiak M. , et al. Artificial dense granules: a procoagulant liposomal formulation modeled after platelet polyphosphate storage pools. Biomacromolecules 2016; 17 (08) 2572-2581
    CrossrefPubMedGoogle Scholar
  • 33 Ghosh S, Shukla D, Suman K. , et al. Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. Blood 2013; 122 (08) 1478-1486
    CrossrefPubMedGoogle Scholar
  • 34 Renné T, Pozgajová M, Grüner S. , et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202 (02) 271-281
    CrossrefPubMedGoogle Scholar
  • 35 Nickel KF, Spronk HM, Mutch NJ, Renné T. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122 (23) 3847-3849
    CrossrefPubMedGoogle Scholar
  • 36 Morrissey JH. Polyphosphate: a link between platelets, coagulation and inflammation. Int J Hematol 2012; 95 (04) 346-352
    CrossrefPubMedGoogle Scholar
  • 37 Alvarenga PH, Xu X, Oliveira F. , et al. Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate. Arterioscler Thromb Vasc Biol 2013; 33 (12) 2759-2770
    CrossrefPubMedGoogle Scholar
  • 38 Jain S, Pitoc GA, Holl EK. , et al. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci U S A 2012; 109 (32) 12938-12943
    CrossrefPubMedGoogle Scholar
  • 39 Smith SA, Choi SH, Collins JN, Travers RJ, Cooley BC, Morrissey JH. Inhibition of polyphosphate as a novel strategy for preventing thrombosis and inflammation. Blood 2012; 120 (26) 5103-5110
    CrossrefPubMedGoogle Scholar
  • 40 Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014; 124 (22) 3183-3190
    CrossrefPubMedGoogle Scholar
  • 41 Labberton L, Kenne E, Long AT. , et al. Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. Nat Commun 2016; 7: 12616
    CrossrefPubMedGoogle Scholar
  • 42 Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renné T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10 (07) 1355-1362
    CrossrefPubMedGoogle Scholar
  • 43 Nickel KF, Ronquist G, Langer F. , et al. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015; 126 (11) 1379-1389
    CrossrefPubMedGoogle Scholar
  • 44 Oschatz C, Maas C, Lecher B. , et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34 (02) 258-268
    CrossrefPubMedGoogle Scholar
  • 45 Sala-Cunill A, Björkqvist J, Senter R. , et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 2015; 135 (04) 1031-43.e6
    CrossrefPubMedGoogle Scholar
  • 46 Maas C, Govers-Riemslag JW, Bouma B. , et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118 (09) 3208-3218
    PubMedGoogle Scholar
  • 47 Zamolodchikov D, Chen ZL, Conti BA, Renné T, Strickland S. Activation of the factor XII-driven contact system in Alzheimer's disease patient and mouse model plasma. Proc Natl Acad Sci U S A 2015; 112 (13) 4068-4073
    CrossrefPubMedGoogle Scholar
  • 48 Zamolodchikov D, Renné T, Strickland S. The Alzheimer's disease peptide β-amyloid promotes thrombin generation through activation of coagulation factor XII. J Thromb Haemost 2016; 14 (05) 995-1007
    CrossrefPubMedGoogle Scholar
  • 49 Göbel K, Pankratz S, Asaridou CM. , et al. Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun 2016; 7: 11626
    CrossrefPubMedGoogle Scholar
  • 50 White-Adams TC, Berny MA, Patel IA. , et al. Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner. J Thromb Haemost 2010; 8 (06) 1295-1301
    CrossrefPubMedGoogle Scholar
  • 51 van der Meijden PE, Munnix IC, Auger JM. , et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009; 114 (04) 881-890
    CrossrefPubMedGoogle Scholar
  • 52 Kannemeier C, Shibamiya A, Nakazawa F. , et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007; 104 (15) 6388-6393
    CrossrefPubMedGoogle Scholar
  • 53 Oehmcke S, Mörgelin M, Herwald H. Activation of the human contact system on neutrophil extracellular traps. J Innate Immun 2009; 1 (03) 225-230
    CrossrefPubMedGoogle Scholar
  • 54 von Brühl ML, Stark K, Steinhart A. , et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209 (04) 819-835
    CrossrefPubMedGoogle Scholar
  • 55 Nickel KF, Renné T. Crosstalk of the plasma contact system with bacteria. Thromb Res 2012; 130 (Suppl. 01) S78-S83
    CrossrefPubMedGoogle Scholar
  • 56 Bock PE, Srinivasan KR, Shore JD. Activation of intrinsic blood coagulation by ellagic acid: insoluble ellagic acid-metal ion complexes are the activating species. Biochemistry 1981; 20 (25) 7258-7266
    CrossrefPubMedGoogle Scholar
  • 57 Björkqvist J, Lecher B, Maas C, Renné T. Zinc-dependent contact system activation induces vascular leakage and hypotension in rodents. Biol Chem 2013; 394 (09) 1195-1204
    CrossrefPubMedGoogle Scholar
  • 58 Siebeck M, Cheronis JC, Fink E. , et al. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors. J Appl Physiol (1985) 1994; 77 (06) 2675-2680
    CrossrefPubMedGoogle Scholar
  • 59 Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanueva GB. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 1992; 267 (27) 19691-19697
    PubMedGoogle Scholar
  • 60 Blossom DB, Kallen AJ, Patel PR. , et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359 (25) 2674-2684
    CrossrefPubMedGoogle Scholar
  • 61 Saito H, Ishihara T, Suzuki H, Watanabe T. Production and characterization of a murine monoclonal antibody against a heavy chain of Hageman factor (factor XII). Blood 1985; 65 (05) 1263-1268
    PubMedGoogle Scholar
  • 62 Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW. A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J Biol Chem 1987; 262 (21) 10140-10145
    PubMedGoogle Scholar
  • 63 Clarke BJ, Côté HC, Cool DE. , et al. Mapping of a putative surface-binding site of human coagulation factor XII. J Biol Chem 1989; 264 (19) 11497-11502
    PubMedGoogle Scholar
  • 64 Citarella F, Fedele G, Roem D, Fantoni A, Hack CE. The second exon-encoded factor XII region is involved in the interaction of factor XII with factor XI and does not contribute to the binding site for negatively charged surfaces. Blood 1998; 92 (11) 4198-4206
    PubMedGoogle Scholar
  • 65 Citarella F, te Velthuis H, Helmer-Citterich M, Hack CE. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII--an immunochemical and homology modeling approach. Thromb Haemost 2000; 84 (06) 1057-1065
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 66 Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Meijers JC, Bouma BN, Hack CE. Activation of the contact system of coagulation by a monoclonal antibody directed against a neodeterminant in the heavy chain region of human coagulation factor XII (Hageman factor). J Biol Chem 1989; 264 (22) 12941-12949
    PubMedGoogle Scholar
  • 67 Ravon DM, Citarella F, Lubbers YT, Pascucci B, Hack CE. Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein. Blood 1995; 86 (11) 4134-4143
    CrossrefPubMedGoogle Scholar
  • 68 Citarella F, Aiuti A, La Porta C. , et al. Control of human coagulation by recombinant serine proteases. Blood clotting is activated by recombinant factor XII deleted of five regulatory domains. Eur J Biochem 1992; 208 (01) 23-30
    CrossrefPubMedGoogle Scholar
  • 69 Larsson M, Rayzman V, Nolte MW. , et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci Transl Med 2014; 6 (222) 222ra17
    CrossrefPubMedGoogle Scholar
  • 70 de Maat S, Björkqvist J, Suffritti C. , et al. Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations. J Allergy Clin Immunol 2016; 138 (05) 1414-1423.e9
    CrossrefPubMedGoogle Scholar
  • 71 Potempa J, Herwald H. Kinins in bacterial infections. In: Bader M. , ed. Kinins. Berlin, Germany: De Gruyter; 2012: 307-320
    Google Scholar
  • 72 Kuijpers MJ, van der Meijden PE, Feijge MA. , et al. Factor XII regulates the pathological process of thrombus formation on ruptured plaques. Arterioscler Thromb Vasc Biol 2014; 34 (08) 1674-1680
    CrossrefPubMedGoogle Scholar
  • 73 van Montfoort ML, Kuijpers MJ, Knaup VL. , et al. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2014; 34 (08) 1668-1673
    CrossrefPubMedGoogle Scholar
  • 74 Cheng Q, Tucker EI, Pine MS. , et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116 (19) 3981-3989
    CrossrefPubMedGoogle Scholar
  • 75 de Maat S, Maas C. Factor XII: form determines function. J Thromb Haemost 2016; 14 (08) 1498-1506
    CrossrefPubMedGoogle Scholar
  • 76 Labberton L, Kenne E, Renné T. New agents for thromboprotection. A role for factor XII and XIIa inhibition. Hamostaseologie 2015; 35 (04) 338-350
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 77 Björkqvist J, Sala-Cunill A, Renné T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109 (03) 368-374
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 78 Cichon S, Martin L, Hennies HC. , et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79 (06) 1098-1104
    CrossrefPubMedGoogle Scholar
  • 79 Björkqvist J, de Maat S, Lewandrowski U. , et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 125 (08) 3132-3146
    CrossrefPubMedGoogle Scholar
  • 80 Bernardi F, Marchetti G, Volinia S. , et al. A frequent factor XII gene mutation in Hageman trait. Hum Genet 1988; 80 (02) 149-151
    CrossrefPubMedGoogle Scholar
  • 81 Miyata T, Kawabata S, Iwanaga S, Takahashi I, Alving B, Saito H. Coagulation factor XII (Hageman factor) Washington D.C.: inactive factor XIIa results from Cys-571----Ser substitution. Proc Natl Acad Sci U S A 1989; 86 (21) 8319-8322
    CrossrefPubMedGoogle Scholar
  • 82 Hovinga JK, Schaller J, Stricker H, Wuillemin WA, Furlan M, Lämmle B. Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353-->Pro leading to loss of a kallikrein cleavage site. Blood 1994; 84 (04) 1173-1181
    CrossrefPubMedGoogle Scholar
  • 83 Schloesser M, Hofferbert S, Bartz U, Lutze G, Lämmle B, Engel W. The novel acceptor splice site mutation 11396(G-->A) in the factor XII gene causes a truncated transcript in cross-reacting material negative patients. Hum Mol Genet 1995; 4 (07) 1235-1237
    CrossrefPubMedGoogle Scholar
  • 84 Hofferbert S, Müller J, Köstering H, von Ohlen WD, Schloesser M. A novel 5′-upstream mutation in the factor XII gene is associated with a TaqI restriction site in an Alu repeat in factor XII-deficient patients. Hum Genet 1996; 97 (06) 838-841
    CrossrefPubMedGoogle Scholar
  • 85 Schloesser M, Zeerleder S, Lutze G. , et al. Mutations in the human factor XII gene. Blood 1997; 90 (10) 3967-3977
    PubMedGoogle Scholar
  • 86 Kanaji T, Okamura T, Osaki K. , et al. A common genetic polymorphism (46.  C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91 (06) 2010-2014
    PubMedGoogle Scholar
  • 87 Kondo S, Tokunaga F, Kawano S, Oono Y, Kumagai S, Koide T. Factor XII Tenri, a novel cross-reacting material negative factor XII deficiency, occurs through a proteasome-mediated degradation. Blood 1999; 93 (12) 4300-4308
    PubMedGoogle Scholar
  • 88 Kanaji T, Kanaji S, Osaki K. , et al. Identification and characterization of two novel mutations (Q421.  K and R123P) in congenital factor XII deficiency. Thromb Haemost 2001; 86 (06) 1409-1415
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 89 Wada H, Nishioka J, Kasai Y. , et al. Molecular characterization of coagulation factor XII deficiency in a Japanese family. Thromb Haemost 2003; 90 (01) 59-63
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 90 Oguchi S, Ishii K, Moriki T. , et al. Factor XII Shizuoka, a novel mutation (Ala392Thr) identified and characterized in a patient with congenital coagulation factor XII deficiency. Thromb Res 2005; 115 (03) 191-197
    CrossrefPubMedGoogle Scholar
  • 91 Lombardi AM, Bortoletto E, Scarparo P, Scapin M, Santarossa L, Girolami A. Genetic study in patients with factor XII deficiency: a report of three new mutations exon 13 (Q501STOP), exon 14 (P547L) and -13C>T promoter region in three compound heterozygotes. Blood Coagul Fibrinolysis 2008; 19 (07) 639-643
    CrossrefPubMedGoogle Scholar
  • 92 Feng Y, Ye X, Pang Y, Dai J, Wang XF, Zhou XH. A novel mutation in a patient with congenital coagulation factor XII deficiency. Chin Med J (Engl) 2008; 121 (13) 1241-1244
    PubMedGoogle Scholar
  • 93 Suzuki K, Murai K, Suwabe A, Ishida Y. Factor XII Ofunato: Lys346Asn mutation associated with blood coagulation factor XII deficiency causes impaired secretion through a proteasome-mediated degradation. Thromb Res 2010; 125 (05) 438-443
    CrossrefPubMedGoogle Scholar
  • 94 Kwon MJ, Kim HJ, Lee KO, Jung CW, Kim SH. Molecular genetic analysis of Korean patients with coagulation factor XII deficiency. Blood Coagul Fibrinolysis 2010; 21 (04) 308-312
    CrossrefPubMedGoogle Scholar
  • 95 Matsuki E, Miyakawa Y, Okamoto S. A novel factor XII mutation, FXII R84P, causing factor XII deficiency in a patient with hereditary spastic paraplegia. Blood Coagul Fibrinolysis 2011; 22 (03) 227-230
    CrossrefPubMedGoogle Scholar
  • 96 Kim HJ, Kim HJ, Kwon EH, Lee KO, Park IA, Kim SH. Novel deleterious mutation in the F12 gene in a Korean family with severe coagulation factor XII deficiency. Blood Coagul Fibrinolysis 2010; 21 (07) 683-686
    PubMedGoogle Scholar
  • 97 Matsukuma E, Gotoh Y, Kuroyanagi Y. , et al. A case of atypical hemolytic uremic syndrome due to anti-factor H antibody in a patient presenting with a factor XII deficiency identified two novel mutations. Clin Exp Nephrol 2011; 15 (02) 269-274
    CrossrefPubMedGoogle Scholar
  • 98 Ye X, Feng Y, Ding Q, Dai J, Wang X. Genetic analysis of a pedigree with combined factor XII and factor XI deficiency. Blood Coagul Fibrinolysis 2011; 22 (02) 118-122
    CrossrefPubMedGoogle Scholar
  • 99 Iijima K, Arakawa Y, Sugahara Y. , et al. Factor XII Osaka: abnormal factor XII with partially defective prekallikrein cleavage activity. Thromb Haemost 2011; 105 (03) 473-478
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 100 Zhang Y, Xie HX, Wang MS, Jin YH, Xie YS, Zheng FX. Analysis of an hereditary coagulation factor XII deficiency in a consanguineous pedigree [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011; 28 (06) 666-669
    PubMedGoogle Scholar
  • 101 Singhamatr P, Kanjanapongkul S, Rojnuckarin P. Molecular analysis of factor XII gene in Thai patients with factor XII deficiency. Blood Coagul Fibrinolysis 2013; 24 (06) 599-604
    CrossrefPubMedGoogle Scholar
  • 102 Xie H, Lv M, Yang X. , et al. Identification of a novel mutation of factor XII gene in a family with coagulation FXII deficiency [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2013; 30 (03) 313-317
    PubMedGoogle Scholar
  • 103 Li M, Xie H, Wang M, Ding H. Molecular characterization of a novel missense mutation (Asp538Asn) in a Chinese patient with Factor XII deficiency. Clin Lab 2015; 61 (12) 1967-1971
    PubMedGoogle Scholar
  • 104 Jin P, Jiang W, Yan H. , et al. Novel mutations in congenital factor XII deficiency. Front Biosci (Landmark Ed) 2016; 21: 419-429
    CrossrefPubMedGoogle Scholar
  • 105 Yang L, Wang Y, Zhou J. , et al. Identification of genetic defects underlying FXII deficiency in four unrelated Chinese patients. Acta Haematol 2016; 135 (04) 238-240
    CrossrefPubMedGoogle Scholar
  • 106 Cool DE, MacGillivray RT. Characterization of the human blood coagulation factor XII gene. Intron/exon gene organization and analysis of the 5′-flanking region. J Biol Chem 1987; 262 (28) 13662-13673
    PubMedGoogle Scholar
  • 107 Tripodi M, Citarella F, Guida S, Galeffi P, Fantoni A, Cortese R. cDNA sequence coding for human coagulation factor XII (Hageman). Nucleic Acids Res 1986; 14 (07) 3146
    CrossrefPubMedGoogle Scholar
  • 108 Kaplan AP, Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987; 70 (01) 1-15
    PubMedGoogle Scholar
  • 109 Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343 (04) 1286-1289
    CrossrefPubMedGoogle Scholar
  • 110 Bork K, Wulff K, Meinke P, Wagner N, Hardt J, Witzke G. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141 (01) 31-35
    CrossrefPubMedGoogle Scholar
  • 111 Kiss N, Barabás E, Várnai K. , et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol 2013; 149 (01) 142-145
    CrossrefPubMedGoogle Scholar